GMAB


Also found in: Idioms.
AcronymDefinition
GMABGive Me A Break
GMABGuaranteed Minimum Accumulation Benefit
GMABGrowth Management Advisory Board (Australia)
GMABGood Money After Bad
GMABGet Me a Beer (slang)
References in periodicals archive ?
(5) A GMAB gives the policyholder the right to receive the greater of the terminal VA account value and a prespecified amount, if he is alive when the policy matures.
On average, the corrosion resistance of the standard-brazed compounds is up to 12% lower for flat samples and up to 11.6% lower for structured samples compared to the best results for flat and structured samples brazed by pulsed GMAB. The pulsed GMA brazing modification through CMT technology demonstrates worse corrosion behavior of all samples.
A guaranteed minimum accumulation benefit (GMAB) rider guarantees that an owner's contract value will be set at least equal to a certain minimum percentage (usually 100 percent) of the amount invested after a specified number of years (typically 10 years), regardless of actual investment performance.
Juan David Ospina Correa, Grupo de Mineralogia Aplicada y Bioprocesos (GMAB), Universidad Nacional de Colombia, Medellin AA 1027.
The company has acquired GMAB's complete turn-key flue gas cleaning plants and energy recovery systems.
McLaughlin also wondered why more life reinsurers didn't come up with their own hedging programs to take on risks such as GMAB. "Why couldn't the reinsurer do that?
These benefits may be such things as lifetime income payments, protections provided by death benefits, guaranteed minimum withdrawal benefits (GMWB), guaranteed minimum withdrawal benefit for life (GWBL), guaranteed minimum income benefits (GMIB), and guaranteed minimum accumulation benefits (GMAB).
GENMAB A/S/S ADR (NASDAQ: GMAB), which recently listed its shares in the U.S., said Novartis AG (NYSE:NVS), its partner in the development of atumumab, has reported positive results for the investigational compound in Phase 3 studies dubbed ASCLEPIOS I and II.
Release date- 22082019 - Copenhagen - Genmab A/S (Nasdaq: GMAB) announced today that the Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the use of DARZALEX (daratumumab) in combination with bortezomib, melphalan and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Genmab A/S (CPH: GMAB), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, reported on Tuesday that it will increase its share capital by 21,811 shares as a consequence of the exercise of employee warrants.
Genmab added that an application has been made to list the ADS on the Nasdaq Global Select Market in the US under the symbol 'GMAB'.
SEC for a proposed public offering of American Depositary Shares and has applied for listing of the ADSs on the Nasdaq Global Select Market under the symbol "GMAB." The Registration Statement relating to these securities has been filed with the SEC but has not yet become effective.